Navigation Links
Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
Date:4/24/2008

BASINGSTOKE, England, April 24 /PRNewswire-FirstCall/ -- The Board of Directors of Shire plc (LSE: SHP) (NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that Michael Rosenblatt M.D. will join the Board as a Non-Executive Director with immediate effect.

Dr Rosenblatt is the Dean of Tufts University School of Medicine, Boston, Massachusetts. He was previously Professor of Medicine at Harvard Medical School and has served in senior research positions at the Beth Israel Deaconess Medical Center in Boston. He was the founding director of the Carl J. Shapiro Institute for Education and Research at Harvard Medical School and Beth Israel Deaconess Medical Center.

In addition, Dr Rosenblatt has served as Director of the Harvard-MIT Division of Health Sciences and Technology and as Senior Vice President for Research at Merck Sharp & Dohme Research Laboratories where he headed a worldwide development team as well as directing drug discovery efforts in the United States, Japan and Italy. In Japan he was responsible for Merck's clinical research and development; he also headed Merck Research's worldwide University and Industry Relations Department.

Earlier in his career, Dr Rosenblatt was Chief of the Endocrine Unit at Massachusetts General Hospital. He is a graduate of Columbia University and gained his medical qualification at Harvard Medical School.

Dr James Cavanaugh, Chairman of Shire commented:

"We are honored to welcome Dr Rosenblatt to the Board of Directors. His impressive medical background and research experience will be of great value as we continue to grow our business through acquisition and product development. As Shire grows its biopharmaceutical portfolio and expands its geographical reach, we will benefit greatly from Michael's expertise and knowledge."

Dr Rosenblatt added:

"Shire stands out in the global pharmaceutical industry with its differentiated model, impressive growth record and exciting pipeline. I'm very pleased to be joining the Shire team at this time in the Company's development."

There are no details that are required to be disclosed under paragraph 9.6.13(1-6) of the Listing Rules of the Financial Services Authority.

Notes to Editors

Further background on Michael Rosenblatt

Fuller Albright Young Investigator Award for 'outstanding scientific achievement' (1986)
Vincent du Vigneaud Award in peptide chemistry and biology

Chairman's Award, Merck (1989)

Soma Weiss Award of the Harvard Medical Society (1973)

Citation of Appreciation, Japan Endocrine Society (1988)

Chaired the Gordon Conference on Chemistry and Biology of peptides

Served on the NIH Physiological Chemistry Study Section On the NIH Board of Scientific Councilors of the National Institute of Diabetes and Digestive and Kidney Diseases

Elected to the American Society of Clinical Investigation

Association of American Physicians

Fellowship in the American Association for the Advancement of Science (1993)

President of the American Societyy of Bone and Mineral Researc

Elected to the Association of Osteobiology (1994)

Testified before a US Senate Hearing on US biomedical research priorities (1997)

Shire PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development including, but not limited to the successful development of JUVISTA(R) (Human TGF(beta)3) and veleglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE(TM) (lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products, including, but not limited to, the impact of those on Shire's ADHD franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, including Shire plc's Annual Report on Form 10-K for the year ended December 31, 2007.


'/>"/>
SOURCE Shire PLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
2. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
3. Genstar Names Michael Hurt to Its Strategic Advisory Board
4. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
5. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
6. Pharmasset Appoints Michael Rogers as Chief Development Officer
7. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
8. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
9. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
10. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
11. John Marshall and Kevin McGuinness Appointed to Ellex Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... Nov. 30, 2016  GenomOncology today announced the appointment of ... Medical Affairs.  Dr. Coleman will oversee clinical ... proprietary knowledge-enabled platform. The GenomOncology software suite empowers molecular pathologists ... data and clinical decision support, from quality control through reporting. ... , , ...
(Date:11/30/2016)... VANCOUVER , Nov. 30, 2016 /PRNewswire/ -  Equicare ... coordination solutions, has been recognized as one of the ... 100, an annual international listing that distinguishes the top ... "We,ve pushed a great step forward this year continually ... growing our own customer base and team," says ...
(Date:11/30/2016)... 30, 2016   Merck , a leading science ... into a set of agreements with Evotec AG, whereby ... of genetic reagents such as CRISPR and shRNA libraries. ... offers an accelerated pathway to explore and identify new ... identification of new targets, a process that can be ...
(Date:11/30/2016)... ... 2016 , ... With growth rates averaging more than 30% each year, Random42 ... to continuing their expansion in their new office space. The new office has a ... by the creative industries, so Random42 Scientific Communication will fit right in. , ...
Breaking Biology Technology:
(Date:6/15/2016)... 15, 2016 Transparency Market ... Recognition Market by Application Market - Global Industry Analysis Size ... to the report, the  global gesture recognition market ... and is estimated to grow at a CAGR ... 2024.  Increasing application of gesture recognition ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
Breaking Biology News(10 mins):